Hepatitis E Diagnostic Tests Market Outlook 2032
The global hepatitis E diagnostic tests market size was USD 87.5 Million in 2023 and is likely to reach USD 134.5 Million by 2032, expanding at a CAGR of 4.9% during 2024–2032. The market growth is attributed to the increasing prevalence of Hepatitis E and growing awareness and screening programs.
Hepatitis E is a liver disease caused by the hepatitis E virus (HEV), one of five human hepatitis viruses. It is transmitted through fecal-oral contact, vertical transmission from a pregnant woman to her baby, transfusion of contaminated blood products, and eating undercooked meat. In areas with inadequate sanitation, infections are widespread, potentially benefiting the global hepatitis E diagnostic tests market in the future.
-
On July 20, 2023, according to the World Health Organization, Hepatitis E is a liver inflammation caused by HEV infection, affecting around 20 million people annually. It causes 3.3 million symptomatic cases and caused around 44,000 deaths in 2015, accounting for 3.3% of viral hepatitis-related mortality,
Hepatitis E cases are not clinically distinct from other acute viral hepatitis but is strongly suspected in epidemiologic settings. Diagnosis is usually based on specific anti-HEV antibodies in blood, with rapid tests available for field use. Additional tests, such as RT-PCR, are needed in infrequent areas and rare cases with chronic HEV infection.
Impact of Artificial Intelligence (AI) in Hepatitis E Diagnostic Tests Market
The impact of Artificial Intelligence (AI) in the hepatitis E diagnostic tests market is substantial, with increasing attention being paid to the application of AI in the diagnosis of diverse hepatic diseases, including hepatitis E. This includes the use of traditional machine learning and deep learning.
AI has been shown to have possible value in predicting the incidence of hepatitis and classifying different hepatic diseases. Furthermore, AI is being utilized to extract rich information from imaging and clinical data to aid in the diagnosis and treatment of liver diseases, including hepatitis E. This demonstrates the potential for AI to significantly improve the diagnostic capabilities in the field of hepatology.
Hepatitis E Diagnostic Tests Market Dynamics
Major Drivers
Increasing prevalence of Hepatitis E is driving the global market. Hepatitis E is becoming a major public health concern in many countries, especially in developing regions where access to proper sanitation and clean drinking water is limited. Moreover, growing awareness and screening programs is driving the need for accurate and efficient diagnostic tests. Early detection and timely treatment are crucial to prevent the transmission of the virus and improve patient outcomes.
Existing Restraints
Limited availability of specific diagnostic tests for Hepatitis E presents significant challenges worldwide. In some regions, particularly low-income countries, there is a lack of awareness about Hepatitis E and limited healthcare infrastructure. This hinders the adoption of diagnostic tests and limits the market. Furthermore, the high cost and in-accessibility of diagnostic tests is restraining the global market.
Emerging Opportunities
Increasing technological advancements and evolution of diagnostics such as PCR-based assays, serological tests, and point of care devices, offers opportunities for the development of an accurate, rapid, and affordable Hepatitis E tests. Increasing focus on point of care testing in various healthcare applications is expected to propel the market significantly during the forecast period.
Scope of the Hepatitis E Diagnostic Tests Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hepatitis E Diagnostic Tests Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2023
|
|
Historic Data
|
2017–2022
|
|
Forecast Period
|
2024–2032
|
|
Segmentation
|
Test Type (ELISA HEV IgM, ELISA HEV IgG, and RT-PCR), and End-users (Hospitals, Diagnostic Centers, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
AccuBioTech Co., Ltd.; Altona Diagnostics GmbH; Beijing Wantai; Dia.Pro Diagnostic Bioprobes s.r.l; F. Hoffmann-La Roche Ltd; Fortress Diagnostics; Gold Standard Diagnostics; Mikrogen GmbH.; MP Biomedicals, LLC; and Primerdesign Ltd
|
Hepatitis E Diagnostic Tests Market Segment Insights
Test Type Segment Analysis
Based on test type, the market is divided into ELISA HEV IgM, ELISA HEV IgG, and RT-PCR. The ELISA HEV IgM segment dominated the global market in 2023 owing to is lower cost and easier use than RT-PCS. ELISA tests are generally cheaper and easier to perform compared to RT-PCR tests. ELISA HEV IgM is specifically designed to detect recent or acute HEV infection, which is a common scenario requiring diagnosis, propelling the segment.
The RT-PCR segment is anticipated to expand at a substantial CAGR during the forecast period owing to its high accuracy. The RT-PCR is considered the gold standard for diagnosing acute HEV infection. Moreover, the growing importance of RT-PCR with the increasing healthcare awareness and access to advanced diagnostics is expected to propel the segment during the forecast period.
End-user Segment Analysis
On the basis of end-user, the global market is segregated into hospitals, diagnostic centers, and others. The hospitals segment is anticipated to expand at a considerable CAGR during the forecast period owing to the extensive infrastructure and wider range of diagnostic equipment. Moreover, the large patient base and availability of various specialists is boosting the segment. Hospitals cater to a large and diverse patient population, including those with acute or severe symptoms suggestive of Hepatitis E. Additionally, the hospitals are well equipped to handle complex cases, thus fueling the segment.
The diagnostic centers segment is projected to register a robust growth during the assessment years owing to high accessibility and focus on specialization. The diagnostic centers are often spread wider than hospitals, particularly in urban and semi-urban areas. Furthermore, the convenience and affordability are expected to boost the segment during the forecast period.
Regional Analysis
In terms of region, the global hepatitis E diagnostic tests market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is expected to dominate the market during the forecast period owing to the rising prevalence of Hepatitis E infection. Moreover, growing healthcare facilities is expected to drive the regional market. The hyper-endemic hepatitis E condition in the region, exacerbated by inadequate sanitation and safe drinking water, is leading to the increased demand for hepatitis E diagnostic tests. Rising awareness and healthcare knowledge and government investments are boosting the market.
The market in Europe is projected to grow at a significant pace in the years to come owing to the top-notch infrastructure. Moreover, increasing technical advancements and increasing awareness of latest technologies is expected to drive the region significantly during the forecast period. Additionally, the increasing consumption of pork and increasing prevalence of pork related infectious diseases is driving the market in the region.
Segments
Test Type
- ELISA HEV IgM
- ELISA HEV IgG
- RT-PCR
End-users
- Hospitals
- Diagnostic Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global hepatitis E diagnostic tests market are AccuBioTech Co., Ltd.; Altona Diagnostics GmbH; Beijing Wantai; Dia.Pro Diagnostic Bioprobes s.r.l; F. Hoffmann-La Roche Ltd; Fortress Diagnostics; Gold Standard Diagnostics; Mikrogen GmbH.; MP Biomedicals, LLC; and Primerdesign Ltd. These companies adopt development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,
-
In June 2019, BioMérieux has launched two VIDAS hepatitis E tests, expanding its hepatitis panel to include tests for A, B, and C, thereby strengthening its market leadership.
Request For Customization
Enquiry Before Buying
Speak With Analyst
